17α-Methyl-4,9,11-oestratrien-17β-ol-3-on

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17α-Methyl-4,9,11-oestratrien-17β-ol-3-on
• 英文别名: 3-Oxo-17α-methyl-17β-hydroxyestra-4,9,11-trien；17α-Methyl-17β-hydroxy-Δ^4,9,11-oestratrien-3-on；4.9.11-Estratrien-17α-methyl-17β-ol-3-on；methyltrienolone；17β-hydroxy-17α-methyl-estra-4,9,11-trien-3-one；(1S,3aS,3bS,11aS)-1-hydroxy-1,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,11aH-cyclopenta[a]phenanthren-7-one；(13S,17S)-17-hydroxy-13,17-dimethyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
• 化学式: C₁₉H₂₄O₂
• 分子量: 284.398
• InChiKey: CCCIJQPRIXGQOE-BTRQGYIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Optical Imaging Contrast Agents for Imaging Lung Cancer
  申请人：Klaveness Jo

  公开号：US20080044350A1

  公开（公告）日：2008-02-21

  The invention provides contrast agents for optical imaging of prostate cancer in patients. The contrast agents may be used in diagnosis of prostate cancer, for follow up of progress in disease development, for follow up of treatment of prostate cancer and for surgical guidance. Further, the invention provides methods for optical imaging of prostate cancer in patients.

  该发明提供了用于患者前列腺癌的光学成像对比剂。这些对比剂可用于前列腺癌的诊断、疾病发展进展的跟踪、前列腺癌治疗的跟踪以及手术指导。此外，该发明还提供了用于患者前列腺癌的光学成像方法。
• ANDROGEN RECEPTOR DOWN-REGULATING AGENTS AND USES THEREOF
  申请人：UNIVERSITY OF MARYLAND EASTERN SHORE

  公开号：US20150361126A1

  公开（公告）日：2015-12-17

  The present disclosure provides the design and synthesis of novel steroidal compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant. The compounds are potential agents for the treatment of all forms of prostate cancer and other diseases that depend on functional AR.

  本公开说明提供了新型类固醇化合物的设计和合成，这些化合物可以导致雄激素受体（AR）的下调，包括全长和剪切变异体。这些化合物是治疗各种前列腺癌和其他依赖于功能性AR的疾病的潜在药物。
• US9439912B2
  申请人：——

  公开号：US9439912B2

  公开（公告）日：2016-09-13
• US9884067B2
  申请人：——

  公开号：US9884067B2

  公开（公告）日：2018-02-06
• [EN] PHARMACEUTICAL COMPOSITION, COMPRISING A STEROID-DEHYDROGENASE-REDUCTASE INHIBITOR, AND A MINERALOCORTICOID RECEPTOR ANTAGONIST<br/>[FR] COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE REDUCTASE DÉSHYDROGÉNASE HYDROXYSTÉROÏDE, ET UN ANTAGONISTE DU RECEPTEUR MINERALOCORTICOÏDE
  申请人：ONTOCHEM GMBH

  公开号：WO2010121814A1

  公开（公告）日：2010-10-28

  A treatment using a hydroxysteroid dehydrogenase reductase inhibitor combined with a mineralocorticoid receptor antagonist is provided which overcomes the problem that manipulating Cortisol levels by a single compound therapy induces other pathologies or side effects, while the original condition that required treatment is ameliorated.